197 related articles for article (PubMed ID: 17638908)
21. Role of MRP4 and MRP5 in biology and chemotherapy.
Sampath J; Adachi M; Hatse S; Naesens L; Balzarini J; Flatley RM; Matherly LH; Schuetz JD
AAPS PharmSci; 2002; 4(3):E14. PubMed ID: 12423063
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
[TBL] [Abstract][Full Text] [Related]
23. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Zhang H; Wang YJ; Zhang YK; Wang DS; Kathawala RJ; Patel A; Talele TT; Chen ZS; Fu LW
Cancer Lett; 2014 Aug; 350(1-2):61-8. PubMed ID: 24747122
[TBL] [Abstract][Full Text] [Related]
24. [Drug resistance mediated by ABC transporters].
Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
[TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage.
Belinsky MG; Guo P; Lee K; Zhou F; Kotova E; Grinberg A; Westphal H; Shchaveleva I; Klein-Szanto A; Gallo JM; Kruh GD
Cancer Res; 2007 Jan; 67(1):262-8. PubMed ID: 17210706
[TBL] [Abstract][Full Text] [Related]
26. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
27. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
28. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
29. Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.
Robillard KR; Hoque T; Bendayan R
J Pharmacol Exp Ther; 2012 Jan; 340(1):96-108. PubMed ID: 21990609
[TBL] [Abstract][Full Text] [Related]
30. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.
Zhang Y; Bressler JP; Neal J; Lal B; Bhang HE; Laterra J; Pomper MG
Cancer Res; 2007 Oct; 67(19):9389-97. PubMed ID: 17909048
[TBL] [Abstract][Full Text] [Related]
31. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
33. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
34. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
35. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
37. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
38. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.
de Wolf C; Jansen R; Yamaguchi H; de Haas M; van de Wetering K; Wijnholds J; Beijnen J; Borst P
Mol Cancer Ther; 2008 Sep; 7(9):3092-102. PubMed ID: 18765824
[TBL] [Abstract][Full Text] [Related]
39. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
Hofman J; Ahmadimoghaddam D; Hahnova L; Pavek P; Ceckova M; Staud F
Pharmacol Res; 2012 Mar; 65(3):312-9. PubMed ID: 22173067
[TBL] [Abstract][Full Text] [Related]
40. Topotecan is a substrate for multidrug resistance associated protein 4.
Tian Q; Zhang J; Chan SY; Tan TM; Duan W; Huang M; Zhu YZ; Chan E; Yu Q; Nie YQ; Ho PC; Li Q; Ng KY; Yang HY; Wei H; Bian JS; Zhou SF
Curr Drug Metab; 2006 Jan; 7(1):105-18. PubMed ID: 16454695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]